Stockreport

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]

Spyre Therapeutics, Inc.  (SYRE) 
PDF Presented new data on SPY003, a potential best-in-class half-life extended anti-IL-23 antibody, demonstrating robust preclinical potency and a greater than three-fold i [Read more]